urolift growth focu
sinc report share vs hc equip suppli index
believ rel weak attribut guidanc
contain number move part includ fairli signific deceler urolift
believ reflect manag conservat onset year
view bigger pictur stori unchangedurolift continu primari driver
growth believ stock valuat larg captur posit outlook
said rais price target slightli better
expect urolift sale give us greater confid sustain growth
warrant higher pe appli vs pe unchang ep
estim maintain equal weight rate larg due valuat
urolifta minim invas treatment enlarg prostat bph continu
drive compani sale growth outlook stock sale
constant currenc basi growth attribut
urolift full year sale urolift contribut
growth urolift sale constant currenc basi
manag guid least growth believ repres
conservat exampl guid initi
manag reiter lrp enter year long rang plan
think sale goal achiev street though
lower end oper margin goal seem like
manag guid organ sale growth exclud impact
steril sale growth would level view
achiev conserv manag guid street owe
continu impact third-parti steril less sell day well fx
maintain ep ep street
one area would like see improv free cash flow
past four year
quarterli annual ep usd
rais usd
return equiti ttm
idc link barclay live interact chart
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
continu grow modestli deceler
success past deal notabl
neotract urolift vsi help acceler
overal growth believ sale growth
achiev warrant premium pe
stock current reflect equal weight
upsid case could driven greater urolift
vsi sale greater improv profit
improv core busi sale growth
rate accret
downsid case could driven slowdown
urolift sale rel expect challeng
within core busi foreign exchang rate
stronger us dollar higher interest rate
despit urolift come significantli ahead expect
sale slightli ahead street/our expect
busi came lighter constant currenc sale growth
driven urolift contribut nearli growth ex-urolift estim
sale rel estim ep beat function
significantli lower tax rate oper margin came expect
guidanc reflect number move part look in-lin adjust
acquisit headwind net/net view unchang
maintain equal weight mainli due valuat
addit detail quarter
million except per share data chang sale constant currenc basi unless otherwis note
intervent urolog urolift sale bloomberg consensu
estim growth y/i repres
strongest quarter year
manag remain confid lrp target organ constant
currenc revenu growth gross margin oper
margin period
exclud urolift sale came weaker expect anesthesia
particularli lower streets/our estim
ep y/i came street estim
howev beat function significantli lower tax rate oper
margin lower expect
manag guid urolift sale least deceler
constant currenc rate sale acceler throughout year
midpoint commentari impli guidanc street impli
sale vs street ep vs street howev
advers affect steril issu coronaviru proportion
higher fx headwind one less sell day
sale report constant currenc basi
gross margin y/i reflect increas sale volum
favor product mix benefit footprint restructur program net
sg sale y/i
 sale flat y/i
oper margin driven gross margin expans
adjust tax rate y/i reflect greater windfal benefit
stock-bas compens
adjust ep y/i exclud effect fx
manag expect revenu fy revenu impli adjust ep expect
fy ep impli estim reflect expect impact steril issu
impact coronaviru well expect fx headwind proportion largest
also one less sell day rel
expect constant currenc revenu growth includ hpc acquisit fx expect
unfavor impact bring report revenu growth adjust gross margin expect
adjust oper margin expect manag expect tax rate interest
expens net/net manag expect adjust ep reflect growth
first look takeaway call pleas see note
 kstew call note focu urolift guidanc left desir
model post barclay live model link
organ growth adjust sell day
urolift sale million
urolift contribut growth estimate unadjust day
urolift minim invas technolog treat lower urinari tract symptom due
benign prostat hyperplasia bph urolift procedur perman implant place
hold prostat tissu away obstruct urin flow minim invas
acquir urolift acquisit neotract octob
million up-front track pay million conting sales-bas
mileston payment view urolift tremend acquisit
boost compani top-lin growth though yet gener signific
increment cash flow return full invest ad mileston
payment made said sale growth continu sale market spend
moder expect gener attract return time
address patient popul urolift extrem larg incid bph
men men men age
urolift sale total million constant currenc basi
view urolift problem surpass million market continu
march toward billion-plu product line
teleflex/neotract view urolift market opportun
courtesi
adapt courtesi per denot neotract intern market estim
unit state american urolog associ aua clinic guidelin
includ urolift standard care option treatment bph view
help drive adopt technolog reimburs rate also favor
physician well provid perspect lastli importantli clinic
data also posit urolift peer-review
public urolift system lowest cathet rate new sustain
erectil ejaculatori dysfunct
though initi focu us opportun estim billion
market intern opportun equal larg sale primarili
uk though work reimburs countri
receiv shonin japanes approv wait receiv reimburs
occur latter end expect gener revenu
japan manag note includ japanes urolift revenu
lrp plan thu revenu repres upsid plan see japanes
market billion market opportun longer term
urolift design urolift expect reduc wast
dispos single-deliveri cartridg instead entir devic improv margin
estim urolift gross margin current mid-to-upp
urolift margin could
next gener urolift urolift origin plan begin roll
howev compani decid delay limit launch around
want expand sale forc make improv devic
competit limit thu far
time acquir neotract invest commun
skeptic whether right asset bph boston scientif
subsequ acquir nxthera rezum system treat bph rezum
also minim approach fundament differ urolift rezum use water
vapor remov excess prostat tissu allevi obstruct flow rezum clear
fda though uptak rezum thu far limit
reimburs well rel concern around side-effect
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
